|
Brain Diseases
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These observations provide a platform for structural modifications of efavirenz to modulate CYP46A1 activity as a therapeutic target of brain disorders such as Alzheimer's disease, for which currently no treatment is available.
|
31845585 |
2019 |
|
Brain Diseases
|
0.020 |
Biomarker
|
group |
BEFREE |
Cholesterol 24-Hydroxylation by CYP46A1: Benefits of Modulation for Brain Diseases.
|
31001737 |
2019 |
|
Neurodegenerative Disorders
|
0.020 |
Biomarker
|
group |
BEFREE |
Increasing evidence suggests that CYP46A1 has a role in the pathogenesis and progression of neurodegenerative disorders, and that increasing its levels in the brain is neuroprotective.
|
31286142 |
2019 |
|
Neurodegenerative Disorders
|
0.020 |
AlteredExpression
|
group |
BEFREE |
These "proof of principle" data may have relevance when using mouse models to mimic human disease and in respect of the increasing possibility of treating human neurodegenerative diseases with pharmaceuticals designed to enhance the activity of CYP46A1 or by adeno-associated virus delivery of CYP46A1.
|
31541728 |
2019 |
|
Cerebrovascular Disorders
|
0.010 |
Biomarker
|
group |
BEFREE |
Polymorphisms of cystatin C (CST3) and cholesterol 24-hydroxylase (CYP46) genes, putative risk factors for cerebrovascular disease, were determined.Results.
|
18511756 |
2008 |
|
Neoplasms
|
0.010 |
AlteredExpression
|
group |
BEFREE |
Ectopic expression of CYP46A1 suppressed cell proliferation and in vivo tumour growth by increasing 24OHC levels.
|
31777202 |
2020 |
|
Tauopathies
|
0.010 |
Biomarker
|
group |
BEFREE |
Therefore, CYP46A1 may be a relevant therapeutic target for Tauopathies and especially for AD.
|
26358780 |
2015 |
|
Mental deterioration
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The combined effects of metabolic syndrome and the apolipoprotein E and CYP46 genotypes on the risk of cognitive decline has yet to be determined among Taiwanese Chinese.
|
24924840 |
2014 |
|
Mental deterioration
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
These findings provide direct evidence that CYP46 and ApoE polymorphisms synergically increase the risk for AD development, and influence on the rate of cognitive decline.
|
15165699 |
2004 |
|
Mental deterioration
|
0.030 |
GeneticVariation
|
phenotype |
BEFREE |
The integrated effect of the cholesterol and CYP46 genotypes on the risk of cognitive decline needs to be determined.
|
21729100 |
2011 |
|
Retinal damage
|
0.010 |
AlteredExpression
|
phenotype |
BEFREE |
Collectively, the data obtained establish metabolic and regulatory significance of CYP46A1 for the retina and suggest pharmacologic activation of CYP46A1 as a potential therapeutic approach to dyslipidemia-induced retinal damage.
|
30448403 |
2019 |
|
Depressed mood
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
The results of the present study indicates the possible anti-depressant effect of EFV and pro-depressive-like effect of VRC in specified doses in mice, raising the possibility that stimulation but not inhibition of cholesterol-24S-hydroxylase may be important in the treatment of depression.
|
28986123 |
2017 |
|
Behavioral and psychological symptoms of dementia
|
0.010 |
Biomarker
|
phenotype |
BEFREE |
In this research paper, our aim is to evaluate the association between the APOE, CYP46, PRNP and PRND genes and the profile of neuropsychiatric symptoms in Polish subjects with AD and mild cognitive impairment (MCI).
|
22453181 |
2012 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association of CYP46 gene polymorphism with sporadic Alzheimer's disease in Chinese Han populations: a meta-analysis.
|
23167762 |
2013 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
These data reveal that CE independently regulate Tau and Aβ and identify a druggable CYP46A1-CE-Tau axis in AD.
|
30686764 |
2019 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
In Alzheimer's disease (AD), CYP46A1 shows prominent expression in astrocytes and around amyloid plaques, whereas CYP27A1 expression decreases in neurons and is not apparent around amyloid plaques but increases in oligodendrocytes.
|
15148325 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
We identified a cluster of polymorphisms in APOE, SOAT1, APOE 5'-untranslated region, OLR1, CYP46A1, LPL, LIPA, and APOA4 conferring significant (p = .0002) susceptibility for Alzheimer's disease.
|
16013913 |
2005 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
The results suggest that the decrease of plasma 24S-hydroxycholesterol/cholesterol in severely affected AD patients is a peripheral marker for loss of cholesterol 24S-hydroxylase in the CNS.
|
10884051 |
2000 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Moreover, this CYP46 polymorphism was associated with higher risk of late-onset sporadic AD in 2 independent populations (odds ratio, 2.16; 95% confidence interval [CI], 1.41-3.32; P<.001).
|
12533085 |
2003 |
|
Alzheimer's Disease
|
0.400 |
AlteredExpression
|
disease |
BEFREE |
These observations provide a platform for structural modifications of efavirenz to modulate CYP46A1 activity as a therapeutic target of brain disorders such as Alzheimer's disease, for which currently no treatment is available.
|
31845585 |
2019 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
In conclusion, our meta-analysis has successfully proved that CC genotype of the CYP46A1 T/C polymorphism could increase the risk of AD, and this effect would be weakened in APOE ε4 non-carriers and strengthened in APOE ε4 carriers.
|
23070465 |
2013 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Lack of association of the cholesterol 24-hydroxylase (CYP46) intron 2 polymorphism with Alzheimer's disease.
|
15331159 |
2004 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
BEFREE |
Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese.
|
15450677 |
2004 |
|
Alzheimer's Disease
|
0.400 |
GeneticVariation
|
disease |
LHGDN |
Association between a T/C polymorphism in intron 2 of cholesterol 24S-hydroxylase gene and Alzheimer's disease in Chinese.
|
15450677 |
2004 |
|
Alzheimer's Disease
|
0.400 |
Biomarker
|
disease |
BEFREE |
Therefore, CYP46A1 may be a relevant therapeutic target for Tauopathies and especially for AD.
|
26358780 |
2015 |